interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Sildenafil Citrate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Sildenafil Citrate, and who makes it?

Sildenafil Citrate appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 24 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 5.4 and 14.6 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Sildenafil Citrate5 dosage-form groups in the Orange Book
24generic makers listed
  1. Sildenafil Citrate appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 24 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 5.4 and 14.6 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Revatio and Viagra. 18 generic makers with 58 generic products listed as marketed; the first generic approval is dated 6 November 2012.

19952000200520102015202020252030018brand 1998Chartwell Rx Sciences Llc, first approval 6 November 2012Torrent Pharmaceuticals Ltd, first approval 6 November 2012Watson Laboratories Inc, first approval 6 November 2012Amneal Pharmaceuticals, first approval 28 February 2013Macleods Pharmaceuticals Ltd, first approval 17 December 2013Hetero Labs Ltd Unit V, first approval 26 November 2014Aurobindo Pharma Ltd, first approval 18 November 2015Teva Pharmaceuticals Usa Inc, first approval 9 March 2016Rubicon Research Ltd, first approval 20 June 2016Ajanta Pharma Ltd, first approval 4 May 2018Amneal Pharmaceuticals Of Ny Llc, first approval 27 June 2018Appco Pharma Llc, first approval 2 March 2020Sunshine Lake Pharma Co Ltd, first approval 11 June 2020Reyoung Corporation, first approval 12 June 2020Umedica Laboratories Private Ltd, first approval 25 August 2020Novitium Pharma Llc, first approval 29 August 2023Cadila Pharmaceuticals Ltd, first approval 28 November 2023Jubilant Generics Ltd, first approval 20 December 2024data dateExclusivity ODE-469 to 31 January 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Chartwell Rx Sciences Llc6 November 20124
Torrent Pharmaceuticals Ltd6 November 20124
Watson Laboratories Inc6 November 20121
Amneal Pharmaceuticals28 February 20131
Macleods Pharmaceuticals Ltd17 December 20134
Hetero Labs Ltd Unit V26 November 20144
Aurobindo Pharma Ltd18 November 20154
Teva Pharmaceuticals Usa Inc9 March 20163
Rubicon Research Ltd20 June 20164
Ajanta Pharma Ltd4 May 20184
Amneal Pharmaceuticals Of Ny Llc27 June 20183
Appco Pharma Llc2 March 20203

6 more makers are listed in the data.

Patents and exclusivities still listed

  • 31 January 2030Exclusivity ODE-469 Revatio

For Suspension, Oral

Four or more generic makers listed

Every brand product here is listed as discontinued. 11 generic makers with 11 generic products listed as marketed; the first generic approval is dated 31 May 2019.

20102015202020252030011brand 2012Novitium Pharma Llc, first approval 31 May 2019Ajanta Pharma Ltd, first approval 27 November 2019Alkem Laboratories Ltd, first approval 27 November 2019Amneal Pharmaceuticals Of New York Llc, first approval 27 November 2019Teva Pharmaceuticals Usa, first approval 29 May 2020Invagen Pharmaceuticals Inc, first approval 6 August 2020Chartwell Rx Sciences Llc, first approval 29 April 2021Hetero Labs Ltd Unit V, first approval 11 May 2021Msn Laboratories Private Ltd, first approval 8 February 2022Zydus Lifesciences Global Fze, first approval 29 September 2022Aurobindo Pharma Ltd, first approval 23 December 2022data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Novitium Pharma Llc31 May 20191
Ajanta Pharma Ltd27 November 20191
Alkem Laboratories Ltd27 November 20191
Amneal Pharmaceuticals Of New York Llc27 November 20191
Teva Pharmaceuticals Usa29 May 20201
Invagen Pharmaceuticals Inc6 August 20201
Chartwell Rx Sciences Llc29 April 20211
Hetero Labs Ltd Unit V11 May 20211
Msn Laboratories Private Ltd8 February 20221
Zydus Lifesciences Global Fze29 September 20221
Aurobindo Pharma Ltd23 December 20221

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Film, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Vybrique. No generic is listed as marketed.

202020252030203501brand 2025data datePatent 11123287 listed to expire 16 December 2033Exclusivity NP to 16 December 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 16 December 2028Exclusivity NP Vybrique
  • 16 December 2033Patent 11123287 drug product

Solution, Intravenous

One to three generic makers listed

Brand listed as marketed: Revatio. 1 generic maker with 1 generic product listed as marketed; the first generic approval is dated 1 April 2015.

20052010201520202025203001brand 2009Eugia Pharma Specialities Ltd, first approval 1 April 2015data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Eugia Pharma Specialities Ltd1 April 20151

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Suspension, Oral

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

20202025203001brand 2023data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.